Scholarlink

Purpose <p>To investigate whether alterations in subfoveal choroidal thickness (SFCT) and peripheral retinal refraction mediate the efficacy of repeated low-level red-light (RLRL) therapy for myopia control.</p> Methods <p>We conducted a mediation analysis within a multicenter, randomized controlled trial. A total of 300 myopic children were included in this analysis. Participants in RLRL group wore single-vision spectacles (SVSs) and received red-light therapy twice daily for 12 months. The control group wore SVSs only, without any additional myopia-control intervention. Axial length (AL), spherical equivalent refraction (SER), SFCT and total refractive difference value (TRDV) were measured at baseline and at follow-up visits over 12 months.</p> Results <p>After 12 months, RLRL therapy significantly attenuated axial length and myopic shift in spherical equivalence compared with controls, accompanied by sustained increases in choroidal thickness and reductions in peripheral hyperopic defocus. Mediation analysis revealed that changes in choroidal thickness and peripheral refraction accounted for 24.83% and 6.79%, respectively, of the effect on axial length inhibition, and 28.79% and 5.97% of the effect on spherical equivalent control. The remaining effects were attributable to the direct impact of red-light (68.39% for axial length and 65.24% for spherical equivalence). Notably, choroidal thickening emerged as the predominant mediator within the first three months.</p> Conclusions <p>RLRL therapy exerted a predominantly direct effect on myopia control, while changes in choroidal thickness and peripheral defocus partially mediated its effectiveness.</p> Trial registration <p>This trial was registered at the Chinese Clinical Trial Registry on January 30, 2021, with trial registration number: ChiCTR2100042836. <a href="https://www.chictr.org.cn/showprojEN.html?proj=120971">https://www.chictr.org.cn/showprojEN.html?proj=120971</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effectiveness of red-light therapy on myopia control depends on its direct effect: a mediation analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Qin Chen,
  • Hongyu Wei,
  • Zhi Da Soh,
  • Qin Zhu,
  • Xian Shao,
  • Cancan Xue,
  • Hengtong Li,
  • Yijin Tao,
  • Min Hu,
  • Ching-Yu Cheng,
  • Hua Zhong

摘要

Purpose

To investigate whether alterations in subfoveal choroidal thickness (SFCT) and peripheral retinal refraction mediate the efficacy of repeated low-level red-light (RLRL) therapy for myopia control.

Methods

We conducted a mediation analysis within a multicenter, randomized controlled trial. A total of 300 myopic children were included in this analysis. Participants in RLRL group wore single-vision spectacles (SVSs) and received red-light therapy twice daily for 12 months. The control group wore SVSs only, without any additional myopia-control intervention. Axial length (AL), spherical equivalent refraction (SER), SFCT and total refractive difference value (TRDV) were measured at baseline and at follow-up visits over 12 months.

Results

After 12 months, RLRL therapy significantly attenuated axial length and myopic shift in spherical equivalence compared with controls, accompanied by sustained increases in choroidal thickness and reductions in peripheral hyperopic defocus. Mediation analysis revealed that changes in choroidal thickness and peripheral refraction accounted for 24.83% and 6.79%, respectively, of the effect on axial length inhibition, and 28.79% and 5.97% of the effect on spherical equivalent control. The remaining effects were attributable to the direct impact of red-light (68.39% for axial length and 65.24% for spherical equivalence). Notably, choroidal thickening emerged as the predominant mediator within the first three months.

Conclusions

RLRL therapy exerted a predominantly direct effect on myopia control, while changes in choroidal thickness and peripheral defocus partially mediated its effectiveness.

Trial registration

This trial was registered at the Chinese Clinical Trial Registry on January 30, 2021, with trial registration number: ChiCTR2100042836. https://www.chictr.org.cn/showprojEN.html?proj=120971.